Adjuvant Hypofractionated Radiotherapy for Prostate Cancer

Hypofractionated radiation therapy is a new type of radiotherapy which has been shown to play a larger role in the treatment of prostate cancer. The aims of the trial were to evaluate the safety and feasibility of adjuvant hypofractionated radiotherapy following radical prostatectomy for prostate cancer.

Trial Details

NCT ID
NCT06335693
Phase
NA
Sponsor
Changhai Hospital
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Radiotherapy
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • ECOG performance status 0-2.
  • Pathologically confirmed prostate cancer and completion of radical prostatectomy.
  • Postoperative pathological staging pT 3a, pT 3b, pT 4, surgical margins (+) or N1; or serum PSA ≥0.1ng/ml at 6 weeks postoperatively; or serum PSA …
  • Expected survival time \>5 years.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →